A Non-interventional Study Evaluating Clinical Utility and Implications on Improved Patient Management of Serum Neurofilament as a Prognostic Marker for Disease Activity in Patients With Relapsing Multiple Sclerosis (FILAXOS)
Latest Information Update: 16 Jan 2025
At a glance
- Drugs Ofatumumab (Primary)
- Indications Multiple sclerosis
- Focus Therapeutic Use
- Acronyms FILAXOS
- Sponsors Novartis Pharmaceuticals
Most Recent Events
- 31 Oct 2024 Planned End Date changed from 30 Aug 2027 to 16 Sep 2027.
- 31 Oct 2024 Planned primary completion date changed from 30 Aug 2027 to 16 Sep 2027.
- 31 Oct 2024 Status changed from not yet recruiting to recruiting.